1. Home
  2. Clinical Topics
  3. FDA approves Exjade to treat excess iron in patients with non-transfusion-dependent thalassemia
Clinical TopicsDrugs and DevicesHealthcare & TechnologyNewsPediatricsWeb Exclusives

FDA approves Exjade to treat excess iron in patients with non-transfusion-dependent thalassemia

Share

On Jan. 23, 2013, the U.S. Food and Drug Administration (FDA) approved the use of Exjade (deferasirox) to treat patients ages 10 years and older who have chronic iron overload resulting from non-transfusion-dependent thalassemia, a milder form of thalassemia. Read more.

Leave a Reply

Your email address will not be published.

Fill out this field
Fill out this field
Please enter a valid email address.

Get your free subscription to NurseLine!

NurseLine Newsletter

  • Hidden

*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.

Recent Posts